The cell and gene therapies (CGT) treat, prevent, and even cure diseases. These methods have the potential to help address the root causes of both genetic and acquired diseases. In recent years, there have been several advances in AI technology have enabled the application of AI in complex operations including CGT. Research spanning from preclinical development to post-market surveillance underscores the growing significance of AI in this context. Its potential to improve and expedite various phases of therapy development and application has become increasingly apparent. The market is expected to grow due to the generation of large and complex healthcare datasets by AI.

The integration of AI is becoming prevalent in the CGT sector, driven by advancements in digital technologies, computing power, and the influx of data. The transformative surge of AI is creating an incredible mark on every field including CGT and anticipated to transform both the ecosystem and value chain of CGT.

Major market players in CGT sector are adopting collaboration and partnerships strategies to gain market share

Technology and pharmaceutical players increasing their investments in AI to expand their businesses. Various companies such as Microsoft, Google, and Thales, amongst others, are investing with emerging players in biopharmaceutical companies to establish themselves in the field of AI in CGT market. For instance, in March 2023, researchers used the Goggles' DeepMind AI system "AlphaFold" to develop a tiny syringe that can inject proteins into the cells. Moreover, in June 2022, Microsoft collaborated with Oxfort BioMedica, UK headquartered company to use their AI technology to make CGT manufacturing easier and cheaper.

Increasing complexities, data breaches, and concerns about data privacy are hindering market growth

While AI has found multiple applications across various industries, its integration into the field of CGT remains somewhat constrained. This limitation primarily stems from the intricate challenges faced by healthcare providers. Similar to other health information technologies, AI raises concerns about data privacy and security. This is especially pertinent in today's landscape, marked by the prevalence of cyberattacks, where patients' protected health information has become a lucrative target for identity thieves and cybercriminals. This aids complexity in the rapid adoption of AI in CGT sector.

High potential of AI technology in genomics and drug discovery is projected to drive market growth opportunities

AI is accelerating R&D in the pharmaceutical industry by efficiently handling complex molecular data. In CGT, AI is optimizing delivery methods through deep learning, allowing for the design of immune-evasive viral vectors, and enhancing treatment effectiveness. For clinical trials, AI streamlines patient recruitment by analyzing medical records and offers a solution in the form of synthetic control arms, reducing costs and ethical concerns.

AI-driven digital twins transform manufacturing for consistent product quality, optimize supply chains, ensure regulatory compliance, streamline processes, and accelerate the development of advanced cell and gene therapies. The transformative potential of AI in the CGT sector is substantial, offering benefits in R&D, manufacturing, and beyond.

Accelerating research, optimizing patient matching, and enhancing treatment outcomes in healthcare with machine learning technology

Machine learning (ML) technology has witnessed remarkable growth in recent years, it is mainly driven by the increasing adoption of AI and data-driven solutions across various industries. ML, a subset of AI, empowers computers to learn and make predictions or decisions without being programmed, making it an invaluable tool for businesses. Natural language processing (NLP) and predictive analytics are also employed in the CGT segment. NLP has the capability to examine unstructured data sourced from medical records, enabling the identification of individuals exhibiting particular symptoms, biomarkers, and/or diagnoses aligning with the inclusion criteria for clinical trials. It is revolutionizing the cell and gene therapy market by accelerating research and development processes, optimizing patient matching, and improving treatment outcomes.

Dominance of clinical trials application fuels growth in AI for CGT market

Clinical trials application segment held the largest market share in the AI in CGT market. Increased revenue from this segment is attributed to substantial investments in research, drug discovery, drug development, and clinical trials for newly developed medications. Factors such as patent expirations, an increasing demand for accelerated clinical trial outcomes, and the need for innovative drug advancements is expected to drive segment growth. Moreover, AI's integration into patient recruitment processes is expected to reduce time and costs, further fueling the demand for AI in CGT market.

Source: Intent Market Research Analysis

Biopharmaceutical companies accounted for highest market share in 2023

Biopharmaceutical companies accounted for highest market share in 2023 owing to widespread applications of AI in various technologies. This trend is attributed to the extensive research efforts and adoption of AI within various biopharmaceutical companies. The widespread applications of AI across diverse technologies have spurred its integration into the strategies and operations of these companies, solidifying their position in the AI in CGT market.

North America's market thrives, fuelled by the strong influence and prevalence of key industry players

North America accounted for the highest market share in 2023 as the region is characterized by an increased inclination towards the advanced and latest digital technologies. The strong and developed healthcare, IT, and telecommunications infrastructure in North America has supported the growth of AI in CGT market. Additionally, the North American market experiences growth fueled by the substantial presence of key industry players.

The acquisition of smaller players and product innovations by major players are driving the market growth

The AI in CGT market is characterized by intense competition due to the presence of numerous international and emerging players. These industry leaders are primarily focused on acquiring smaller players and innovating their product lines to cater to changing consumer preferences and needs.

• In July 2023, Généthon and Thales collaborated to develop digital models for improving gene therapy bio-production yields. The objective of this collaboration is to improve production yields, reducing the production costs of innovative therapy drugs
• In July 2023, CF Foundation funds Nosis Bio to design gene therapy using AI
• In September 2022, WhiteLab Genomics raises $10.0 million for AI-powered genomic therapies platform.
• In August 2022, IBM Research REPROCELL and STFC announced a new initiative using AI to advance the discovery of new drug cell and gene therapies and improve the design of clinical trials. This collaboration aims to build discovery-driven communities that make a lasting impact, including in the areas of drug discovery, CGT and clinical trial
• In July 2021, NJII partnered with McKinsey & Company to establish a new center aimed at advancing manufacturing excellence and operations in the field of CGT

AI in Cell and Gene Therapy Market Coverage

The report provides key insights into the AI in cell and gene therapy market, and it focuses on technological developments, trends, and initiatives taken by the government in this sector. The report delves into market drivers, restraints, and opportunities, and analyses key players as well as the competitive landscape within the market

Report Scope